Posterior Uveitis

1. Comprehensive Executive Overview

Posterior uveitis (ICD-10: H30.0) is a serious, potentially sight-threatening inflammatory condition affecting the back segment of the eye. Specifically, it involves inflammation of the choroid (the vascular layer beneath the retina), the retina itself (chorioretinitis or retinochorioretinitis), the vitreous humor, and occasionally the optic nerve head.

Unlike anterior uveitis, which primarily affects the iris and ciliary body and presents with a red, painful eye, posterior uveitis is typically painless and characterized by progressive vision loss, floaters, and visual distortions.

[Uveal Tract]
├── Anterior Uveitis (Iris, Ciliary Body) -> Pain, Redness, Photophobia
├── Intermediate Uveitis (Vitreous, Pars Plana) -> Floaters, Blurred Vision
└── Posterior Uveitis (Choroid, Retina) -> Painless Vision Loss, Floaters, Scotomas

Because the posterior segment contains structures essential for high-acuity vision (such as the macula and optic nerve), uncontrolled inflammation can lead to rapid, irreversible damage. Prompt identification, comprehensive diagnostic workup, and targeted therapeutic intervention are paramount to preserving visual function and preventing chronic disability.

2. Detailed Pathophysiology, Etiology, and Risk Factors

Pathophysiology

The blood-retinal barrier (BRB) consists of inner (retinal vascular endothelial cells) and outer (retinal pigment epithelium - RPE) components. Under normal physiological conditions, the BRB isolates the inner eye from the systemic immune system.

In posterior uveitis, this barrier is disrupted by either infectious pathogens or autoimmune-mediated processes:
1. Leukocyte Extravasation: Inflammatory cytokines (e.g., TNF-alpha, IL-1, IL-6) upregulate adhesion molecules on the vascular endothelium, allowing T-lymphocytes, macrophages, and neutrophils to infiltrate the choroid and retina.
2. Vitreous Haze & Debris: Inflammatory cells and protein exudates spill into the vitreous cavity, resulting in vitritis.
3. Tissue Destruction: Active chorioretinal lesions lead to localized necrosis of photoreceptors and the RPE. Upon healing, these areas form atrophic chorioretinal scars, causing permanent visual field defects.

Etiology

The causes of posterior uveitis are broadly categorized into infectious, non-infectious (autoimmune), and masquerade syndromes.

Risk Factors

• Genetic Predisposition: Specific Human Leukocyte Antigen (HLA) alleles significantly increase susceptibility (e.g., HLA-A29 in Birdshot Chorioretinopathy, HLA-B51 in Behçet's disease).
• Systemic Autoimmune Disease: Diagnoses such as sarcoidosis, inflammatory bowel disease (IBD), or systemic lupus erythematosus (SLE).
• Immunosuppression: HIV/AIDS, post-transplant immunosuppressive therapy, or active chemotherapy predispose patients to opportunistic viral and fungal posterior uveitis.
• Geographic/Environmental Exposure: Exposure to undercooked meat or cat feces (Toxoplasmosis), or living in tuberculosis-endemic regions.

3. Signs, Symptoms, and Clinical Presentation

Patients presenting with posterior uveitis often do not exhibit the classic "red eye" associated with anterior uveitis. Instead, symptoms are primarily visual and insidious in onset.

Key Symptoms

• Floaters (Myodesopsia): Described as spots, cobwebs, or shadows moving across the vision, caused by inflammatory cells and protein aggregates in the vitreous humor.
• Painless Vision Loss: Mild blurring to severe loss of central visual acuity, depending on macular involvement.
• Metamorphopsia: Distortion of straight lines, typically indicating macular edema or subretinal fluid.
• Photopsia: Flashing lights, indicating mechanical traction on the retina or active outer retinal inflammation.
• Scotomas: Fixed blind spots in the visual field corresponding to active or scarred chorioretinal lesions.

[Active Posterior Uveitis]
└── Vitreous Infiltration (Floaters)
└── Macular Edema (Metamorphopsia & Blurred Vision)
└── Retinal Necrosis/Scarring (Permanent Scotomas)

Clinical Signs (On Ophthalmoscopic Examination)

• Vitritis: Graded from 0 to 4+ based on vitreous haze. Severe vitritis obscures the view of the optic nerve and retinal vessels.
• Chorioretinal Lesions: Active lesions appear as soft, yellow-white, elevated areas with ill-defined borders. Inactive lesions are well-demarcated atrophic scars with hyperpigmented borders.
• Retinal Vasculitis: Inflammatory sheathing of retinal veins (periphlebitis, common in sarcoidosis) or retinal arteries (arteritis, common in acute retinal necrosis).
• Cystoid Macular Edema (CME): Fluid accumulation in Henle’s fiber layer of the macula, presenting as a "flower-petal" pattern on imaging.
• Optic Disc Hyperemia/Edema: Secondary to adjacent choroidal inflammation or direct optic nerve involvement (neuroretinitis).

4. Standard Diagnostic Evaluation & Workup

A meticulous, multi-modal diagnostic approach is essential to differentiate infectious from non-infectious etiologies before initiating therapy, as immunosuppressive treatment can be catastrophic in the presence of an untreated infection.

Ophthalmic Imaging (The Gold Standards)

1. Optical Coherence Tomography (OCT)

High-resolution, cross-sectional retinal imaging used to evaluate:
* Subretinal and intraretinal fluid (Cystoid Macular Edema).
* Epiretinal membrane (ERM) formation.
* Vitreomacular traction.
* Retinal pigment epithelium (RPE) disruptions.

2. Fluorescein Angiography (FA)

An intravenous dye test evaluating the retinal vasculature:
* Hyperfluorescence: Demonstrates vascular leakage, optic disc staining, and active chorioretinal lesions.
* Hypofluorescence: Indicates blockage (due to vitreous haze or hemorrhage) or retinal capillary non-perfusion (ischemia).

3. Indocyanine Green Angiography (ICGA)

Utilizes a dye that fluoresces in the near-infrared spectrum, allowing visualization of the deeper choroidal circulation. It is the gold standard for detecting sub-clinical choroidal lesions in conditions like VKH, Birdshot, and sympathetic ophthalmia.

4. Fundus Autofluorescence (FAF)

A non-invasive imaging modality that maps lipofuscin distribution in the RPE. Active inflammatory lesions show hyper- or hypo-autofluorescence, providing a metabolic map of disease activity and progression.

[Diagnostic Imaging Selection]
├── Macular Edema Evaluation? ──────> Optical Coherence Tomography (OCT)
├── Retinal Vasculitis/Leakage? ────> Fluorescein Angiography (FA)
└── Deep Choroidal Lesions? ────────> Indocyanine Green Angiography (ICGA)

Laboratory Assays & Systemic Workup

Based on clinical suspicion, a tailored laboratory panel is ordered:

• Infectious Screening:
• Syphilis: Treponemal (FTA-ABS, TP-PA) and non-treponemal (RPR, VDRL) antibody tests.
• Tuberculosis: QuantiFERON-TB Gold in-tube test or Purified Protein Derivative (PPD) skin test.
• Toxoplasmosis: Serum IgG and IgM antibodies.
• Viral PCR: Aqueous or vitreous humor tap for HSV, VZV, and CMV DNA.
• Autoimmune & Inflammatory Screening:
• Sarcoidosis: Serum Angiotensin-Converting Enzyme (ACE), serum lysozyme, and chest X-ray or high-resolution chest CT (HRCT).
• HLA Typing: HLA-A29 (Birdshot), HLA-B51 (Behçet's), HLA-B27 (associated with panuveitis).

Invasive Diagnostic Procedures

• Diagnostic Anterior Chamber (AC) Tap or Pars Plana Vitrectomy (PPV): Performed when the diagnosis remains elusive, or masquerade syndrome (e.g., intraocular lymphoma) is highly suspected. The fluid is analyzed for PCR (viral/parasitic), cytology, flow cytometry, and cytokine levels (e.g., IL-6 to IL-10 ratio).

5. Therapeutic Interventions

The primary goals of therapy are to suppress intraocular inflammation, eliminate any underlying infectious pathogen, prevent structural damage (such as macular scarring), and preserve visual acuity.

Pharmacotherapy

1. Corticosteroids

Corticosteroids remain the first-line anti-inflammatory treatment for non-infectious posterior uveitis.

• Systemic Corticosteroids: Oral Prednisone (typically initiated at 1 mg/kg/day and gradually tapered over months) is used for bilateral, severe disease or when systemic manifestations are present.
• Local Corticosteroids: Used for unilateral disease or to avoid systemic side effects.
• Periocular Injections: Triamcinolone acetonide (Kenalog) delivered via sub-Tenon's or transseptal injection.
• Intravitreal Injections/Implants:
  • Dexamethasone intravitreal implant (Ozurdex), lasting 3 to 6 months.
  • Fluocinolone acetonide implant (Retisert or Yutiq), providing sustained release for up to 36 months.

2. Immunomodulatory Therapy (IMT) / Steroid-Sparing Agents

Indicated for patients who cannot tolerate systemic corticosteroids, require >10 mg/day of prednisone long-term, or have specific diseases where early IMT is standard of care (e.g., Behçet's disease, VKH).

• Antimetabolites: Methotrexate, Mycophenolate Mofetil (CellCept), Azathioprine.
• T-cell Inhibitors: Cyclosporine, Tacrolimus.
• Biologics (Anti-TNF-alpha): Adalimumab (Humira) is FDA-approved for non-infectious intermediate, posterior, and panuveitis. Infliximab (Remicade) is also highly effective, particularly in Behçet's disease.

3. Targeted Antimicrobial Therapy

Mandatory for all infectious etiologies. Systemic or local corticosteroids are only introduced after or concurrently with appropriate antimicrobial coverage to control host-mediated inflammatory damage.

• Toxoplasmosis: Triple therapy (Pyrimethamine, Sulfadiazine, and oral Leucovorin) or oral Clindamycin / Trimethoprim-Sulfamethoxazole.
• CMV Retinitis: Intravitreal Ganciclovir injections combined with systemic Valganciclovir.
• Syphilis: Intravenous Penicillin G for 10–14 days (treated as neurosyphilis).
• Tuberculosis: Standard multi-drug anti-tubercular therapy (Rifampin, Isoniazid, Pyrazinamide, Ethambutol) for 6 to 9 months.

Surgical Interventions

• Pars Plana Vitrectomy (PPV): Indicated for clearing dense vitreous opacities that do not resolve with medical therapy, treating tractional retinal detachments, repairing macular holes, or managing epiretinal membranes.
• Glaucoma Surgery: If steroid-induced or inflammatory glaucoma cannot be controlled with topical medications, surgical options like trabeculectomy or glaucoma drainage devices (e.g., Ahmed or Baerveldt valves) are warranted.
• Cataract Extraction: Often required due to cataract progression from chronic inflammation or prolonged corticosteroid use. It is crucial to perform this surgery only after the eye has been completely quiet (inflammation-free) for at least 3 months.

Prognosis & Long-Term Monitoring

The prognosis of posterior uveitis is highly variable and depends on the underlying etiology, the promptness of treatment, and the occurrence of complications.

[Potential Long-Term Complications]
├── Cystoid Macular Edema (CME) ──> Leading cause of permanent central vision loss
├── Secondary Glaucoma ───────────> Optic nerve damage from elevated IOP
├── Cataracts ────────────────────> Lens opacification from inflammation/steroids
└── Choroidal Neovascularization ─> Abnormal vessel growth leading to subretinal hemorrhage

Regular follow-up visits, including visual acuity testing, intraocular pressure monitoring, and periodic OCT imaging, are mandatory to detect sub-clinical recurrences and manage treatment-related side effects.

6. Frequently Asked Questions (FAQs)

Q1: What is the primary difference between anterior and posterior uveitis?

Anterior uveitis affects the front part of the eye (iris and ciliary body) and typically presents with eye redness, pain, and sensitivity to light (photophobia). Posterior uveitis affects the back of the eye (choroid, retina, and vitreous) and is usually painless, presenting primarily with floaters, blurry vision, and blind spots.

Q2: Can posterior uveitis cause permanent blindness?

Yes, if left untreated or poorly managed, posterior uveitis can cause permanent, irreversible blindness. This occurs due to complications such as chronic cystoid macular edema, retinal scarring, optic nerve atrophy, or retinal detachment. Early diagnosis and strict adherence to treatment are vital to preserving vision.

Q3: Is posterior uveitis a hereditary condition?

While the condition itself is not directly inherited in a simple genetic pattern, a genetic predisposition exists. Certain genetic markers, such as HLA-A29 (associated with Birdshot Chorioretinopathy) and HLA-B51 (associated with Behçet's disease), increase an individual's susceptibility to developing specific types of autoimmune posterior uveitis.

Q4: What is the most common cause of posterior uveitis?

Globally, the most common infectious cause of posterior uveitis is ocular toxoplasmosis, caused by the parasite Toxoplasma gondii. Among non-infectious, autoimmune causes, sarcoidosis, Vogt-Koyanagi-Harada (VKH) disease, and birdshot chorioretinopathy are highly prevalent, depending on the patient's demographic and geographic region.

Q5: How is posterior uveitis linked to systemic autoimmune diseases?

The eye shares common immunological pathways with other organs. In systemic autoimmune diseases like sarcoidosis, inflammatory bowel disease, or lupus, the body's immune system mistakenly attacks healthy tissues, including the vascular layers of the eye (the uvea). A diagnosis of posterior uveitis often prompts a comprehensive medical workup to evaluate for these systemic diseases.

Q6: What are the side effects of long-term steroid treatment for uveitis?

Corticosteroids are highly effective but carry significant risk with prolonged use.
* Ocular side effects: Accelerated cataract formation, elevated intraocular pressure (which can lead to steroid-induced glaucoma), and increased susceptibility to secondary ocular infections.
* Systemic side effects (oral steroids): Weight gain, osteoporosis, hypertension, hyperglycemia/diabetes, mood swings, and increased susceptibility to systemic infections.

Q7: How long does it take for posterior uveitis to clear up?

The recovery timeline varies significantly. Acute infectious cases (like toxoplasmosis) may resolve within 6 to 12 weeks with appropriate antimicrobial therapy. Chronic, autoimmune forms of posterior uveitis can persist for years, requiring long-term maintenance therapy with steroid-sparing immunomodulatory drugs to keep the disease in remission.

Q8: Can stress trigger a flare-up of posterior uveitis?

Yes, clinical observation suggests that physiological and psychological stress can trigger or worsen flare-ups of autoimmune posterior uveitis. Stress elevates systemic cortisol and inflammatory cytokine levels, which can disrupt immune regulation and lead to a breakthrough of intraocular inflammation.

Q9: Is exercise safe during an active flare of posterior uveitis?

During an active flare, strenuous exercise, heavy lifting, or high-impact activities should be avoided, especially if you have active vitritis, a risk of retinal detachment, or have recently received periocular or intravitreal steroid injections. Gentle walking is generally safe, but you should consult your ophthalmologist for personalized guidance.

Q10: What is the role of biologics like Humira in treating posterior uveitis?

Biologics, such as Adalimumab (Humira), are targeted monoclonal antibodies that inhibit tumor necrosis factor-alpha (TNF-alpha), a key inflammatory cytokine. Humira is FDA-approved for non-infectious intermediate, posterior, and panuveitis. It provides a highly effective, steroid-sparing option for patients who do not respond to traditional immunosuppressants or who experience intolerable side effects from corticosteroids.

Related Clinical Integration

In the management of posterior uveitis, a multidisciplinary approach is essential to control intraocular inflammation and prevent permanent vision loss. Therapeutic intervention typically begins with the administration of corticosteroids, such as Dexamethasone / ديكساميثازون 4 mg/mL, to rapidly suppress acute inflammatory responses, while refractory or chronic cases often necessitate the introduction of systemic immunomodulatory agents like Methotrexate / ميثوتريكسات 2.5mg to achieve long-term disease remission and steroid-sparing effects. In instances where the disease process results in significant vitreous opacification, non-resolving macular edema, or complications such as retinal detachment, surgical intervention via Pars Plana Vitrectomy (PPV) / استئصال الزجاجية عبر الجزء المسطح (عملية كبرى في غرف العمليات) is indicated to clear the visual axis and facilitate diagnostic sampling or targeted drug delivery.